Phillip Pang - 21 Jun 2022 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role: Chief Medical Officer
Signature: /s/ Howard Horn, Attorney-in-Fact
Issuer symbol: VIR
Transactions as of: 21 Jun 2022
Net transactions value: -$124,209
Form type: 4
Filing time: 22 Jun 2022, 17:40:30 UTC
Previous filing: 24 Feb 2022
Next filing: 21 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VIR	Common Stock	Gift	$0	-7,777	-5%	$0.000000	148,991	15 Apr 2022	Direct
transaction	VIR	Common Stock	Sale	$124,209	-4,991	-3.3%	$24.89	144,000	21 Jun 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2022.
F2	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.55 to $25.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 28, 2022.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.55 to $25.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.